Metabolic syndrome is not a single disease but a cluster of interrelated metabolic abnormalities that together produce a cardiovascular and diabetes risk far greater than any of the components would generate individually. It is extremely common, affecting approximately one in three American adults, and its prevalence increases with age. Yet many patients who have it don’t know it, because no single number on a lab report or doctor’s note says ‘metabolic syndrome.’
At Dr. Maryam Khan’s primary care practice in Lutherville-Timonium, MD, identifying metabolic syndrome is part of routine clinical evaluation for patients with any of its individual components. Understanding what it is, and what to do about it, is the first step.
Diagnostic Criteria: When Do the Components Add Up to Metabolic Syndrome?
Metabolic syndrome is diagnosed when three or more of the following five criteria are present, using the joint statement from the American Heart Association and National Heart, Lung, and Blood Institute (AHA/NHLBI):
| Criterion | Threshold for Metabolic Syndrome |
| Waist circumference | Greater than 40 inches in men; greater than 35 inches in women (lower for Asian patients) |
| Triglycerides | 150 mg/dL or above, OR on medication for elevated triglycerides |
| HDL cholesterol | Below 40 mg/dL in men; below 50 mg/dL in women, OR on medication for low HDL |
| Blood pressure | 130/85 mmHg or above, OR on antihypertensive medication |
| Fasting glucose | 100 mg/dL or above (pre-diabetes threshold), OR on medication for elevated blood sugar |
A patient who has hypertension on medication, borderline fasting glucose, and a large waist circumference meets the criteria for metabolic syndrome, even if each individual abnormality seems modest in isolation.
Why the Combination Matters More Than the Parts
The components of metabolic syndrome do not simply add their risks together, they amplify each other. Insulin resistance drives central adiposity, which drives dyslipidemia (elevated triglycerides, low HDL), which drives hypertension, which drives further metabolic deterioration. The interconnected nature of these abnormalities reflects a shared underlying pathophysiology centered on insulin resistance and the inflammatory effects of visceral adipose tissue.
People with metabolic syndrome face:
• A 2-fold increased risk of cardiovascular disease compared to those without the syndrome
• A 5-fold increased risk of developing Type 2 diabetes
• Elevated risk of non-alcoholic fatty liver disease, polycystic ovary syndrome, and certain cancers
The Root Cause: Insulin Resistance and Visceral Adiposity
While metabolic syndrome has multiple contributing factors including genetics, aging, and physical inactivity, its common thread is insulin resistance, a state in which cells throughout the body respond poorly to insulin, requiring the pancreas to produce more insulin to achieve the same glucose-lowering effect. Visceral fat (fat stored around the abdominal organs) is particularly insulin-resistant and metabolically active, secreting inflammatory cytokines (adipokines) that promote the entire syndrome.
This is why waist circumference, a proxy for visceral adiposity, is one of the five diagnostic criteria, and why lifestyle interventions targeting central adiposity are the most effective treatments for metabolic syndrome.
Primary Care Treatment of Metabolic Syndrome
Lifestyle Intervention: The Foundation
Lifestyle modification is the most effective treatment for metabolic syndrome and the necessary foundation regardless of whether pharmacological treatment is added:
• Weight loss of 7 to 10% of body weight reduces insulin resistance, lowers triglycerides, raises HDL, reduces blood pressure, and decreases fasting glucose, improving all five diagnostic criteria simultaneously
• Physical activity of 150 minutes per week of moderate intensity reduces insulin resistance independently of weight loss, exercise has direct metabolic effects on skeletal muscle glucose uptake
• Dietary modification: reducing refined carbohydrates and added sugars, increasing dietary fiber, adopting Mediterranean or DASH dietary patterns
• Alcohol reduction: heavy alcohol use elevates triglycerides and blood pressure and should be reduced or eliminated
Pharmacological Management of Individual Components
Metabolic syndrome itself does not have a single pharmacological treatment. Instead, Dr. Khan manages each elevated component to its clinical target:
• Hypertension: ACE inhibitors or ARBs are preferred first-line agents, particularly when glucose is also elevated, because they have favorable metabolic profiles and provide kidney protection
• Dyslipidemia: Elevated triglycerides respond well to omega-3 fatty acids, fibrates, and in some cases niacin. Statins address LDL reduction and cardiovascular risk independently. Low HDL is primarily addressed through lifestyle (exercise, smoking cessation).
• Pre-diabetes or impaired fasting glucose: Metformin reduces progression to diabetes. GLP-1 receptor agonists address glucose, weight, blood pressure, and triglycerides simultaneously, making them particularly well-suited for patients with metabolic syndrome.
GLP-1 Medications for Metabolic Syndrome
GLP-1 receptor agonists (semaglutide, tirzepatide) are particularly valuable in patients with metabolic syndrome because they address multiple components simultaneously: weight reduction, glucose improvement, triglyceride reduction, and modest blood pressure lowering. For patients with metabolic syndrome and BMI meeting approval criteria, these medications may be the single most efficient pharmacological intervention available.
Monitoring and Follow-Up
Metabolic syndrome requires ongoing monitoring because its components can worsen over time and because treatment response varies. Dr. Khan monitors metabolic labs (lipid panel, fasting glucose, liver enzymes), blood pressure, and waist circumference at regular intervals, adjusting the treatment plan based on trajectory. Early and consistent primary care management of metabolic syndrome is the most effective way to prevent its progression to cardiovascular disease and Type 2 diabetes.
| For metabolic syndrome evaluation and treatment in Timonium, MD, contact Dr. Maryam Khan, MD at (443) 577-4010. Located at 1205 York Rd, Suite 11, Lutherville-Timonium, MD 21093. Medicare and commercial insurance accepted. Accepting new patients in Baltimore County. |